Profile data is unavailable for this security.
About the company
Polarean Imaging PLC is a medical-imaging technology company, with an investigational drug-device combination product for magnetic resonance imaging (MRI). The Company and its subsidiary company operate as investigational drug-device combination companies operating in the high-resolution medical imaging research space. The Company develops equipment that enables existing MRI systems to achieve an improved level of pulmonary functional imaging and specializes in the use of hyperpolarized xenon gas (129Xe) as an imaging agent to visualize ventilation. 129Xe gas is being studied for visualization of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream. The Company’s technology provides an investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform. It operates in Canada, Germany, United Kingdom and United States. The Company’s subsidiary is Polarean, Inc.
- Revenue in GBP (TTM)690.32k
- Net income in GBP-9.21m
- Incorporated2016
- Employees29.00
- LocationPolarean Imaging PLC2500 Meridian Pkwy #175DURHAM 27713United StatesUSA
- Phone+1 (919) 206-7900
- Fax+1 (919) 206-7901
- Websitehttps://polarean.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abingdon Health PLC | 5.34m | -2.24m | 13.62m | 82.00 | -- | 7.21 | -- | 2.55 | -0.0184 | -0.0184 | 0.0439 | 0.0149 | 0.8978 | 7.67 | 4.74 | 65,170.73 | -37.55 | -51.31 | -58.04 | -79.85 | 57.35 | 33.16 | -41.82 | -139.64 | 1.59 | -- | 0.3572 | -- | 42.68 | -- | 83.77 | -- | -- | -- |
| Inspiration Healthcare Group PLC | 37.63m | -6.32m | 17.04m | 210.00 | -- | 0.4476 | -- | 0.4527 | -0.0925 | -0.0925 | 0.5516 | 0.4245 | 0.7243 | 1.67 | 3.66 | -- | -12.17 | 0.8965 | -14.86 | 1.10 | 47.53 | 47.61 | -16.80 | 0.9922 | 0.9698 | -0.9172 | 0.307 | -- | -8.74 | 19.43 | -2,423.90 | -- | 31.88 | -- |
| Verici DX PLC | 3.36m | -3.73m | 18.19m | 19.00 | -- | 2.38 | -- | 5.42 | -0.0204 | -0.0204 | 0.0171 | 0.0315 | 0.4038 | -- | 5.71 | 239,809.90 | -44.82 | -- | -58.12 | -- | 77.06 | -- | -110.99 | -- | -- | -- | 0.0183 | -- | -- | -- | 23.43 | -- | -- | -- |
| Genedrive PLC | 272.00k | -5.00m | 22.00m | 43.00 | -- | 4.12 | -- | 80.87 | -0.0407 | -0.0407 | 0.0022 | 0.0098 | 0.0658 | -- | 1.60 | 6,325.58 | -120.84 | -97.55 | -197.86 | -128.51 | -- | -- | -1,837.50 | -797.03 | 1.36 | -7.49 | 0.0789 | -- | 12.24 | -50.95 | -10.16 | -- | 16.72 | -- |
| Polarean Imaging PLC | 690.32k | -9.21m | 22.03m | 29.00 | -- | 0.7182 | -- | 31.91 | -0.0367 | -0.0367 | 0.0028 | 0.0254 | 0.0533 | 0.2824 | 0.7599 | 23,804.11 | -71.12 | -61.45 | -81.95 | -69.17 | 37.66 | 50.68 | -1,333.98 | -810.92 | 3.11 | -- | 0.0255 | -- | -13.75 | -18.24 | 14.53 | -- | 64.51 | -- |
| Renalytix PLC | 2.64m | -35.81m | 22.40m | 80.00 | -- | 0.8854 | -- | 8.49 | -0.4384 | -0.4384 | 0.0321 | 0.1525 | 0.0646 | 2.88 | 4.06 | 32,959.33 | -87.73 | -58.25 | -120.00 | -67.03 | 20.60 | -- | -1,358.30 | -1,904.79 | 1.71 | -9.62 | 0.397 | -- | 14.58 | -- | 18.52 | -- | -- | -- |
| Belluscura PLC | 639.55k | -14.35m | 22.73m | 24.00 | -- | 1.35 | -- | 35.55 | -0.1087 | -0.1087 | 0.0049 | 0.0997 | 0.0372 | 0.2118 | 0.1975 | -- | -83.37 | -49.84 | -96.68 | -54.78 | -50.80 | -37.48 | -2,243.45 | -1,277.34 | 1.71 | -4.07 | -- | -- | -40.96 | 27.44 | -127.13 | -- | 41.32 | -- |
| Ondine Biomedical Inc | 675.11k | -8.09m | 22.83m | 43.00 | -- | 15.96 | -- | 33.82 | -0.0411 | -0.0411 | 0.0034 | 0.0052 | 0.1079 | 0.4237 | 4.74 | -- | -129.24 | -- | -193.37 | -- | 58.44 | -- | -1,198.01 | -- | 1.06 | -- | 0.206 | -- | 88.56 | -- | 25.60 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Rathbones Investment Management Ltd.as of 18 Jun 2024 | 60.25m | 4.99% |
| Unicorn Asset Management Ltd.as of 30 Jun 2024 | 38.18m | 3.16% |
| Yarra Investment Management Ltd.as of 28 Feb 2023 | 10.65m | 0.88% |
| Chelverton Asset Management Ltd.as of 28 Feb 2023 | 9.96m | 0.83% |
| Canaccord Genuity Wealth Ltd.as of 28 Feb 2023 | 8.34m | 0.69% |
| Aviva Investors Global Services Ltd.as of 30 Apr 2024 | 614.76k | 0.05% |
| Premier Fund Managers Ltd.as of 29 Dec 2023 | 509.69k | 0.04% |
| Thornbridge Investment Management LLPas of 31 Oct 2022 | 322.81k | 0.03% |
